TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00658008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 175 mg BID, 8 weeks with 2 week taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 225 mg BID, 8 weeks with 2 week taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 75 mg BID, 8 weeks with 2 week taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, oral, placebo bid, 8 weeks with 2 week taper
Study: NCT02884531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education and Basic Body Awareness Therapy
Description: Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Patient education (1/2 day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education (1/2 day)
Study: NCT03277690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.
Study: NCT00550849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 5 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 25 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 50 mg oral capsules
Study: NCT01691898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
Study: NCT02870543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phytolacca decandra
Description: Treatment of bruxism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melissa officinalis
Description: Treatment of bruxism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melissa officinalis
Description: Treatment of bruxism

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melissa officinalis
Description: Treatment of bruxism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyt.decandra + Melissa offic.
Description: Treatment of bruxism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyt.decandra + Melissa offic.
Description: Treatment of bruxism

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phyt.decandra + Melissa offic.
Description: Treatment of bruxism
Study: NCT02551354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable video pupillometer
Description: Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
Study: NCT02611648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double HLD
Description: Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLD/ETO
Description: Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
Study: NCT00361309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
Study: NCT02856711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed group
Description: The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood.
Study: NCT02611414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Description: tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
Study: NCT05293301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning
Description: Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning
Description: Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
Study: NCT01168401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV GI.1/GII.4 Bivalent VLP Vaccine
Description: 2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Two doses 28 days apart
Study: NCT03352388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy- and berry-based snacks
Description: High-protein dairy-based products and energy-enriched berry products for three months
Study: NCT02858934

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface.
Study: NCT00678327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT03083522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ojeok-San
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT03559361

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich
Description: 6 months omega 3 supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich
Description: 6 months omega 3 supplementation
Study: NCT00678327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT03559361

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil Placebo
Description: 6 months placebo supplementation
Study: NCT02375321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP and Psychological support
Description: Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
Study: NCT01444287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon B
Description: test product

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymacon
Description: marketed product

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A
Description: marketed product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spectacles
Description: None - subject used own spectacles
Study: NCT03458780

Intervention type: DRUG
Intervention: Yellow Fever Vaccine
Description: Yellow Fever Vaccine .5 ml
Study: NCT02596906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
Study: NCT00689156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, cyclophosphamide and docetaxel
Description: Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cyclophosphamide
Description: Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
Study: NCT00450892

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel+lapatinib
Description: 3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel + trastuzumab
Description: 3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + trastuzumab + lapatinib
Description: 3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100
Study: NCT00678327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT02024308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
Study: NCT01702896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2
Study: NCT01392755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: oral doses of danoprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: oral doses of danoprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: oral doses of omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: oral dose of ranitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses of ritonavir
Study: NCT01306019

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
Description: Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. If the result is not available in time to adjust, then proceed to give the standard 3mg/kg on the second day

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. If the result is not available in time to adjust, then proceed to give the standard 3mg/kg on the second day

Intervention type: DRUG
Group type: OTHER
Intervention: Palifermin
Description: Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration

Intervention type: DRUG
Group type: OTHER
Intervention: Palifermin
Description: Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
Study: NCT01401335

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: questionnaires at entry, month 4, 8 and 12
Study: NCT00929981

Intervention type: DRUG
Intervention: Tablet Methylprednisolone (4 or 16 mg)
Description: Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
Study: NCT02798328

Intervention type: DEVICE
Intervention: TEG6s DOAC Cartridge
Description: Testing subjects for presence of DOAC

Intervention type: DEVICE
Intervention: TEG6s DOAC Cartridge
Description: Testing subjects for presence of DOAC
Study: NCT03634059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
Study: NCT03509285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprazolam Placebo
Description: 100 mg lactose tablets
Study: NCT01392755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses of ritonavir
Study: NCT01551615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Description: 2 x 500 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib 800 mg
Description: 2 x 300 mg and 2 x 100 mg oral tablets
Study: NCT03208270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin supplementation
Description: antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No antithrombin supplementation
Description: supplementation of antithrombin will not be provided unless heparin resistance occurs
Study: NCT03426280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch Series 1
Description: Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
Study: NCT03474562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duowell®
Description: Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova® + Amlopin®
Description: Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
Study: NCT01769781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrazole
Description: combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analog alone
Description: treatment for three months with GnRH analog (leuprolide acetate) alone
Study: NCT04268563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral rehydration solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin
Description: Sitagliptin/metformin tablet
Study: NCT04114877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional retraining (AR)
Description: Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. AR is the most commonly used CBM intervention in the study of addiction-related attentional bias. The idea behind AR is to reduce attentional bias and therefore minimize exposure to drug cues, because attention to such stimuli may provoke craving and undermine cessation attempts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual probe (VP)
Description: The visual probe (VP) task can measure attentional bias for drug-related cues. In the typical VP task, a pair of pictures or words (e.g. one smoking-related and one neutral) is briefly presented simultaneously side by side on a computer screen. After the pictures disappear, a probe stimulus (e.g. a small dot) is presented in the location that had been occupied by one of the pictures (or words), and participants are required to press a key as quickly as possible in response to the probe. Attentional bias for drug-related cues is detected by a faster response to a probe that replaces a drug-related stimulus (vs. a neutral stimulus), since attention will have been preferentially allocated to that area of visual display. The traditional VP task only assesses attentional bias, and does not modify it in any way.
Study: NCT04756635

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental Group
Description: This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
Study: NCT00815412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling in use of health care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling in diet, exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control